AstraZeneca PLC (AZN)
Healthcare • Drug Manufacturers - General
StockLSEUnited KingdomGB0009895292
140.46 GBP
+0.83% today Updated 13 Nov 2026 16:21
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by AstraZeneca PLC, and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in GBP. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 16:21. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Next results
09 Feb 2027
in 88 days · 11:00 · estimate 2.37
Last results
2.79 vs 2.59 estimated
30 Oct 2026 · Beat +7.9%
Beat the estimate
9 of 12
1 missed · 2 in line · 5 beats in a row
Average surprise
+3.7%
reported against the estimate, last 12 quarters
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 09 Feb 2027 11:00 | 2.37 | — | — | Upcoming |
| 30 Oct 2026 02:00 | 2.59 | 2.79 | +7.9% | Beat |
| 27 Jul 2026 02:00 | 2.47 | 2.63 | +6.3% | Beat |
| 29 Apr 2026 02:00 | 2.52 | 2.58 | +2.4% | Beat |
| 10 Feb 2026 02:00 | 2.08 | 2.12 | +2.0% | Beat |
| 06 Nov 2025 02:00 | 2.27 | 2.38 | +4.9% | Beat |
| 29 Jul 2025 02:00 | 2.15 | 2.17 | +0.9% | In line |
| 29 Apr 2025 02:00 | 2.24 | 2.49 | +11.4% | Beat |
| 06 Feb 2025 02:00 | 2.08 | 2.09 | +0.3% | In line |
| 12 Nov 2024 02:00 | 2.04 | 2.08 | +1.8% | Beat |
| 25 Jul 2024 02:00 | 1.94 | 1.98 | +2.0% | Beat |
| 25 Apr 2024 02:00 | 1.94 | 2.06 | +6.3% | Beat |
| 08 Feb 2024 02:00 | 1.48 | 1.45 | -2.2% | Miss |
| 09 Nov 2023 02:00 | 1.66 | 1.73 | +4.3% | Beat |
| 28 Jul 2023 02:00 | 1.98 | 2.15 | +8.8% | Beat |
| 27 Apr 2023 02:00 | 1.71 | 1.92 | +12.4% | Beat |
| 09 Feb 2023 02:00 | 1.33 | 1.38 | +3.4% | Beat |
| 10 Nov 2022 02:00 | 1.51 | 1.67 | +10.7% | Beat |
| 29 Jul 2022 02:00 | 1.57 | 1.72 | +9.8% | Beat |
| 29 Apr 2022 02:00 | 1.68 | 1.89 | +12.2% | Beat |
| 10 Feb 2022 02:00 | 1.55 | 1.67 | +7.7% | Beat |
| 12 Nov 2021 02:00 | 1.25 | 1.08 | -13.9% | Miss |
| 29 Jul 2021 02:00 | 0.90 | 0.90 | -0.4% | In line |
| 30 Apr 2021 02:00 | 1.45 | 1.63 | +12.1% | Beat |
| 11 Feb 2021 02:00 | 1.10 | 1.07 | -2.3% | Miss |
| 05 Nov 2020 02:00 | 0.99 | 0.94 | -4.9% | Miss |
| 30 Jul 2020 02:00 | 0.92 | 0.96 | +4.7% | Beat |
| 29 Apr 2020 03:00 | 0.93 | 1.05 | +13.3% | Beat |
| 14 Feb 2020 02:00 | 1.00 | 0.89 | -10.7% | Miss |
| 24 Oct 2019 02:00 | 0.95 | 0.99 | +3.8% | Beat |
| 25 Jul 2019 02:00 | 0.60 | 0.73 | +21.4% | Beat |
| 26 Apr 2019 02:00 | 0.84 | 0.89 | +6.1% | Beat |
| 14 Feb 2019 02:00 | 1.47 | 1.58 | +7.2% | Beat |
| 08 Nov 2018 02:00 | 0.65 | 0.71 | +8.4% | Beat |
| 26 Jul 2018 02:00 | 0.63 | 0.69 | +9.6% | Beat |
| 18 May 2018 02:00 | 0.63 | 0.48 | -23.4% | Miss |
| 02 Feb 2018 02:00 | 0.82 | 1.30 | +58.0% | Beat |
| 09 Nov 2017 02:00 | 1.09 | 1.12 | +2.5% | Beat |
| 27 Jul 2017 02:00 | 0.82 | 0.87 | +6.3% | Beat |
| 27 Apr 2017 02:00 | 0.82 | 0.99 | +21.5% | Beat |
| 02 Feb 2017 02:00 | 1.13 | 1.21 | +7.1% | Beat |
| 10 Nov 2016 02:00 | 0.99 | 1.32 | +33.8% | Beat |
| 28 Jul 2016 02:00 | 0.83 | 0.83 | +0.4% | In line |
| 29 Apr 2016 02:00 | 0.96 | 0.95 | -1.0% | In line |
| 04 Feb 2016 02:00 | 0.91 | 0.94 | +2.8% | Beat |
| 05 Nov 2015 02:00 | 1.00 | 1.03 | +2.9% | Beat |
| 30 Jul 2015 02:00 | 1.08 | 1.21 | +11.9% | Beat |
| 24 Apr 2015 02:00 | 1.09 | 1.08 | -0.6% | In line |
| 05 Feb 2015 02:00 | 0.83 | 0.76 | -8.3% | Miss |
| 06 Nov 2014 02:00 | 1.04 | 1.05 | +1.0% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 58.7B | +8.6% | 10.2B | 17.4% | 6.54 | +45.3% | 8.7B |
| 2024 | 54.1B | +18.0% | 7B | 13.0% | 4.50 | +18.1% | 7.3B |
| 2023 | 45.8B | +3.3% | 6B | 13.0% | 3.81 | +80.6% | 6.6B |
| 2022 | 44.4B | — | 3.3B | 7.4% | 2.11 | — | 7.2B |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 137.04 | 143.12 | 134.58 | 140.46 | +0.62% | 27,391,458 | |
| Oct 2026 | 120.14 | 140.02 | 117.16 | 139.60 | +13.68% | 55,249,415 | |
| Sep 2026 | 116.50 | 127.88 | 115.52 | 122.80 | +2.59% | 68,347,235 | |
| Aug 2026 | 118.42 | 124.76 | 114.04 | 119.70 | -5.24% | 86,769,096 | 0.7950 |
| Jul 2026 | 141.38 | 146.86 | 98.92 | 126.32 | -10.41% | 63,836,524 | |
| Jun 2026 | 137.02 | 151.26 | 112.32 | 141.00 | +2.16% | 48,531,480 | |
| May 2026 | 138.10 | 141.20 | 117.98 | 138.02 | -1.05% | 40,927,488 | |
| Apr 2026 | 148.96 | 154.50 | 123.56 | 139.48 | -5.05% | 42,177,064 | |
| Mar 2026 | 151.80 | 154.50 | 134.78 | 146.90 | -5.48% | 60,639,115 | |
| Feb 2026 | 135.32 | 157.32 | 134.44 | 155.42 | +14.28% | 62,339,275 | 1.5950 |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in GBP, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- AstraZeneca (LSE:AZN) Reaffirms Guidance As Pipeline Strength Keeps Undervaluation In View (opens in a new tab) Simply Wall St. · 10 Nov 2026 23:16
- AstraZeneca (LSE:AZN) Stock Fair Value Edges Higher After Mixed Analyst Target Changes (opens in a new tab) Simply Wall St. · 10 Nov 2026 22:11
- AstraZeneca bolsters vaccine pipeline with US-biotech Omniose acquisition (opens in a new tab) Reuters · 10 Nov 2026 14:29
- Drugmaker CEOs Say AI Alone Can't Cure Diseases, Challenge Silicon Valley's Bold Predictions: 'To Say AI Is Going to Cure Cancer...' (opens in a new tab) Benzinga · 05 Nov 2026 15:30
- AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say (opens in a new tab) Reuters · 04 Nov 2026 22:21
- AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals (opens in a new tab) The Wall Street Journal · 04 Nov 2026 22:21
- RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report (opens in a new tab) Stocktwits · 04 Nov 2026 22:20
- Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report (opens in a new tab) Investing.com · 04 Nov 2026 21:53
- AstraZeneca (LSE:AZN) Filing Acceptance In Europe And Japan Puts Lung Cancer Combo Forward (opens in a new tab) Simply Wall St. · 04 Nov 2026 15:11
- Health Care Roundup: Market Talk (opens in a new tab) The Wall Street Journal · 03 Nov 2026 22:03
- AstraZeneca results reassure on long-term growth as three brokers raise price targets (opens in a new tab) Proactive · 02 Nov 2026 14:00
- Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience (opens in a new tab) BioPharma Dive · 02 Nov 2026 14:00
- SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus (opens in a new tab) Stocktwits · 02 Nov 2026 06:11
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 139.30 GBP
- Market cap
- 216.0B
- Dividend yield
- 0.02%
- 5-year average yield
- 2.03%
- Payout ratio
- 45%
- Last dividend
- 0.0080 GBP · 06 Aug 2026
- Exchange
- LSE
- Country
- United Kingdom
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Currency
- GBP
Dividends
| Ex-dividend date | Per share |
|---|---|
| 06 Aug 2026 | 0.7950 GBP |
| 19 Feb 2026 | 1.5950 GBP |
| 07 Aug 2025 | 0.7670 GBP |
| 20 Feb 2025 | 1.6800 GBP |
| 8 older dividends: create a free account to see them | |
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Yield Dividends per year as a share of today's price. Very high yields count for less: they often signal trouble. | 0.1 / 25 |
|
| Dividend safety Can the company keep paying? The dividend against free cash flow and earnings, plus debt and interest cover. | 23.4 / 25 |
|
| Dividend growth How many years in a row the dividend has risen, and how fast. | 7.4 / 15 |
|
| Quality Return on equity, net margin and how stable the margins are. | 12.5 / 15 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 6.3 / 10 |
|
| Analysts How far the analysts' average target is from today's price. | 4.2 / 5 |
|
Income profile: it pays a dividend, so it is scored mainly on the dividend and how safe it is. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 26.37× | Weak | 30.56× |
| P/E (forward) | 16.37× | Fair | 14.16× |
| Price / book | 5.58× | Weak | 3.5× |
| Price / sales | 3.45× | Fair | 3.33× |
| EV / EBITDA | 11.36× | Fair | 11.19× |
| Free cash flow yield | 2.6% | Fair | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 81.8% | Good | 54.9% |
| Operating margin | 25.8% | Good | 5.8% |
| Net margin | 17.7% | Good | 1.2% |
| Return on equity | 22.6% | Good | 4.4% |
| Return on assets | 8.6% | Good | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 9.8% | Good | 10.1% |
| EPS growth / year | 45.8% | Good | 10.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 0.66× | Good | 0.4× |
| Net debt / EBITDA | 1.23× | Good | 1.46× |
| Interest cover | 8.26× | Good | 2.17× |
| Current ratio | 1.01× | Fair | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 45.4% | Good | 0% |
| Payout of free cash flow | 88.3% | Weak | 28.7% |
| Payout of free cash flow (3 years) | 62.5% | Fair | — |
| Dividend growth / year | 7.1% | Good | 6.5% |
| Years of rising dividends | 1 | Weak | 1.5 |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow AZN and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.